banner
 
bar

program

  slides
bar
 
 

Questions and Answers in Cardiovascular Anesthesiology—

Acute Blood Pressure Management
in Cardiovascular Surgery

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

June 1, 2009

Expiration Date:

June 1, 2011

Intended Audience:

  • Cardiologists, non-invasive specialists
  • Cardiovascular anesthesiologists
  • Prevention-oriented cardiologists
  • Cardiologists, invasive specialists
  • Cardiovascu lar nurses
  • Coronary care unit (CCU) specialists and directors
  • Specialists in invasive vascular management
  • Program direc tors, cardiovascular medicine
  • Fellows in cardiovascular medi cine
  • Clinical pharmacists and pharmacologists
  • Pharmacy directors (cardiovascular medicine)
  • Investigators and clinical trial specialists, invasive cardiology

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheSupported by an independent educational grant from The Medicines Company.
 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Jerrold H. Levy, MD– Program Co-Chairman
Professor and Deputy Chair for Research
Emory University School of Medicine
Director of Cardiothoracic Anesthesiology
Cardiothoracic Anesthesiology and Critical Care Emory Healthcare
Atlanta, GA

Consultant: The Medicines Company
Speaker’s Bureau: The Medicines Company


Solomon Aronson, MD – Program Co-Chairman
Professor of Anesthesiology
Duke University Medical Center
Executive Vice Chairman
Department of Anesthesiology
Durham, NC

No Information to Disclose

Edwin G. Avery, IV, MD
Chief, Division of Cardiac Anesthesia
Massachusetts General Hospital
Assistant Professor
Department of Anesthesia and Critical Care
Harvard Medical School
Boston, MA

Grant/Research: The Medicines Company
Consultant: The Medicines Company
Speaker’s Bureau: The Medicines Company

Educational Objectives:

Participants in this CME-certified WebCAST will:

  • Learn to manage the hemodynamic derangements and complications of serious and/or life-threatening elevations in systolic and/or diastolic blood pressure in the perioperative setting.

  • Learn how to select among intravenous pharmacologic agents, including calcium channel blockers/dihydropyridines that are indicated for blood pressure control in the setting of cardiovascular disease.

  • Learn how landmark trials and analyses focusing on BP re duction may have an impact on current and future strategies for management of BP elevations in the setting of cardiovascular surgery.

  • Understand the efficacy and safety profiles of specific pharmacologic agents used for anesthesiology-based control of systemic blood pressure.

  • Be able to discuss the potential impact that new agents will have on future manage ment of patients with BP elevation in the perioperative setting.

Disclaimer:

Copyright © 2009 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

  slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2009 All rights reserved


 
6

 

Key Program Topics Include:

b-blockers
ACE Inhibitors
Acute coronary syndrome
Acute heart failure
Acute Myocardial Infarction
Acute Pressure Syndromes
Acute pulmonary edema
Acute renal failure
Anticoagulants
Antiplatelets
Aortic coarctation
Arrhythmia
ASA
aspirin
BP
Brain
Calcium Channel Blockers
Cardiopulmonary
Chest pain
Clevidipine
Clonidine
clopidogrel
CNS
Cushing’s syndrome
CVA

diabetes
Diastolic
Diazoxide
Dihydropyridine
Dissecting aorta
Diuretics
Dyspnea
Eclampsia
Elevated ICP
Emergency
End-Organ Damage
Epistaxis
Esmolol
Essential hypertension
Exudates
Fenoldopam
GP Iib/IIIa antagonist
Headache
Heart
Hemodynamics
Myocardial Ischemia
Heparin
Hydralazine
Hyperparathyroidism
Hypertension

 

Hypertensive
hypertensive crisis
Hypertensive Emergencies
Hypertensive encephalopathy
Hyperthyroidism
Isolated Systolic Hypertension
Kidneys
Labetolol
LMWH
Low molecular weight heparin
Lytic
MAP
MgSO4
Neurologic deficits
Neurologic Insult
Neurovascular Insults
Nicardipine
Nitrendipine
Nitroglycerin
Nitroprusside
Nitrovasodilators
Ocular
Organic Nitrates
Papilledema
PCWP
Perioperative hypertension
Pheochromocytoma
JNC 7
Pregnancy
Pregnancy-Induced HTN
Prehypertension
Primary aldosteronism
Psychomotor agitation
Rapid Onset of Effect
Reflex tachycardia
Renal
Renal dysfunction
Retinal hemorrhages
Secondary hypertension
Stage 1 hypertension
Stage 2 hypertension
Stage 3 hypertension
Systolic
UFH
Vascular Dysfunction Syndromes
VELOCITY